natgillin/translations-raw huggingface dataset:
ACE-hæmmere og angiotensin II-receptorantagonister bør ikke anvendes samtidigt hos patienter med diabetisk nefropati.
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.
Der er ikke set tegn på teratogen effekt hos rotter, der fik en kombination af irbesartan/hydrochlorthiazid i doser, som forårsager maternel toksicitet.
No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at doses that produced maternal toxicity.
Thiazidbehandling skal seponeres, før parathyreoideafunktionen undersøges.
Thiazides should be discontinued before carrying out tests for parathyroid function.
Risikofaktorer for at udvikle akut snævervinklet glaukom kan omfatte allergi over for sulfonamider eller antibiotika i anamnesen (se pkt.
Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy (see section 4.8).
Irbesartan/Hydrochlorthiazid Teva er en kombination af to aktive stoffer, irbesartan og hydrochlorthiazid.
Irbesartan/Hydrochlorothiazide Teva is a combination of two active substances, irbesartan and hydrochlorothiazide.
Dobbelt hæmning af renin-angiotensin-aldosteron-systemet (RAAS) Der er tegn på, at samtidig brug af ACE-hæmmere og angiotensin II-receptorantagonister eller aliskiren øger risikoen for hypotension, hyperkaliæmi og nedsat nyrefunktion (inklusive akut nyresvigt).
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).
Irbesartan/Hydrochlorthiazid Teva er en kombination af en angiotensin-II-receptorantagonist, irbesartan, og et thiaziddiuretikum, hydrochlorthiazid.
Irbesartan/Hydrochlorothiazide Teva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Den anbefalede dosis af Irbesartan/Hydrochlorthiazid Teva er en tablet dagligt.
The recommended dose of Irbesartan/Hydrochlorothiazide Teva is one tablet a day.
Er du i tvivl, så spørg lægen eller på apoteket.
If you have any further questions, ask your doctor or pharmacist.
Aplastisk anæmi, knoglemarvsdepression, neutropeni/agranulocytose, hæmolytisk anæmi, leukopeni, trombocytopeni
Aplastic anaemia, bone marrow depression, neutopenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
• hvis du har symptomer som voldsom tørst, mundtørhed, følelse af svaghed, sløvhed, muskelsmerter eller -kramper, kvalme, opkastning eller en voldsom hjertebanken, som kan være tegn på for kraftig effekt af hydrochlorthiazid (der er indeholdt i Irbesartan/Hydrochlorthiazid Teva)
if you are on a low-salt diet if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in Irbesartan/Hydrochlorothiazide Teva).
Aktivt stof
Drug substance
Der er ingen erfaring med administration af Irbesartan/Hydrochlorthiazid Teva til nyligt nyretransplanterede patienter.
There is no experience regarding the administration of Irbesartan/Hydrochlorothiazide Teva in patients with a recent kidney transplantation.
Advarselstegn på væske- eller elektrolytforstyrrelser kan være mundtørhed, tørst, svækkelse, sløvhed, døsighed, rastløshed, muskelsmerter eller kramper, muskulær træthed, hypotension, oliguri, takykardi og gastrointestinale forstyrrelser, såsom kvalme og opkastning.
Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.
Det reproduktive system og mammae
Reproductive system and breast disorders:
I dyrestudier med irbesartan sås forbigående toksisk effekt (øget nyrebækkenkavitation, hydroureter eller subkutant ødem) hos rottefostre.
Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth.
Dosisjustering af Irbesartan/Hydrochlorthiazid Teva til ældre personer er ikke nødvendig.
No dosage adjustment of Irbesartan/Hydrochlorothiazide Teva is necessary in older people.
Det anbefales at stoppe behandlingen, hvis fotosensitivitetsreaktioner opstår under behandlingen.
If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment.
Blod og lymfesystem
Blood and lymphatic system disorders:
Kaliumbesparende diuretika, kaliumtilskud eller kaliumholdige saltsubstitutioner skal derfor gives med forsigtighed sammen med Irbesartan/Hydrochlorthiazid Teva (se pkt.
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Irbesartan/Hydrochlorothiazide Teva (see section 4.5).
Irbesartan/Hydrochlorthiazid Teva frarådes tidligt i graviditeten, og du må ikke tage Irbesartan/Hydrochlorthiazid Teva, hvis du er længere end 3 måneder henne i din graviditet, da det kan skade dit barn alvorligt, hvis det tages i denne periode (se afsnittet om graviditet).
Irbesartan/Hydrochlorothiazide Teva is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Der er indberettet bivirkninger efter markedsføring af kombinationen af irbesartan og hydrochlorthiazid.
Some undesirable effects have been reported since the marketing of the combination of irbesartan and hydrochlorothiazide.
Interstitiel nefritis, nyreinsufficiens
Interstitial nephritis, renal dysfunction
Det kan også være nødvendigt at genoverveje, om hydrochlorthiazid bør anvendes hos patienter, der tidligere har haft non-melanom hudkræft (se også pkt.
The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).
Brug af lægemidler, der indeholder sulfonamid eller et sulfonamidderivat, kan medføre en idiosynkratiske reaktion, som kan forårsage forbigående myopi og akut snævervinklet glaukom.
Acute Myopia and Secondary Acute Angle-Closure Glaucoma Sulfonamide drugs or sulfonamide derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angle-closure glaucoma.
Polyethylenglycol 6000 (Macrogol) Polyethylenglycol 400 (Macrogol) Rød jernoxid
Polyethylene Glycol 6000 (Macrogol) Polyethylene Glycol 400 (Macrogol) Iron Oxide Red
Der sås en klar kumulativ dosis/respons relation, hvad angår både basalcellekarcinom og pladecellekarcinom.
A clear cumulative dose response relationship was observed for both BCC and SCC.
Tabel 2 og 3 viser bivirkningerne af de individuelle stoffer i Irbesartan/Hydrochlorthiazid Teva.
Tables 2 and 3 below detail the adverse reactions reported with the individual components of Irbesartan/Hydrochlorothiazide Teva.
Udtalelsen fremsættes ud fra følgende betragtninger:
The other ingredients are:
Serum-kalium påvirkes ikke nævneværdigt, når irbesartan administreres alene ved de anbefalede doser til patienter, uden udvikling af elektrolytforstyrrelser (se pkt.
Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses in patients without risk of electrolyte imbalance (see sections 4.4 and 4.5).
Baseret på erfaringer med andre præparater, som dæmper renin-angiotensinsystemet, har det omvendt vist sig, at samtidig brug af kaliumbesparende diuretika, kaliumtilskud, kaliumholdige salterstatninger eller andre præparater, der kan øge serum-kalium, fx heparinnatrium, kan øge serum-kalium.
Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium.
Irbesartan/Hydrochlorthiazid Teva pakket i hvide, uigennemsigtige PVC-PVdC-aluminiumblistere: Må ikke opbevares ved temperaturer over 30 °C.
For Irbesartan/Hydrochlorothiazide Teva packaged in white opaque PVC-PVdC - aluminium blisters: Do not store above 30°C.
Disse 24-timers resultater blev observeret uden der opstod overdreven reduktion af blodtrykket på det maksimale niveau.
These 24-hour effects were observed without excessive blood pressure lowering at peak and are consistent with safe and effective blood-pressure lowering over the once-daily dosing interval.
Følgende bivirkninger er indberettet i medicinske forsøg med patienter, som fik kombinationen af irbesartan og hydrochlorthiazid:
Side effects reported in clinical studies for patients treated with the combination of irbesartan and hydrochlorothiazide were:
• hvis du samtidig tager et af følgende lægemidler til behandling af for højt blodtryk: en ACE-hæmmer (f.eks. enalapril, lisinopril, ramipril), især hvis du har nyrerproblemer i forbindelse med sukkersyge aliskiren
- an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
Forud for planlagt graviditet skal der skiftes til anden hensigtsmæssig behandling.
A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.
• Øvrige indholdsstoffer: Tabletkerne: Povidon, prægelatineret stivelse (majs), poloxamer 188, mikrokrystallinsk cellulose, croscarmellosenatrium, kolloid vandfri silica og magnesiumstearat.
Tablet core: povidone, pregelatinized starch (maize), poloxamer 188, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and magnesium stearate.
prækliniske sikkerhedsstudier medførte store doser irbesartan (≥ 250 mg/kg/dag hos rotter og
In non clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques)
Bivirkninger fra placebokontrollerede studier og bivirkninger rapporteret efter markedsføring
Adverse Reactions In Placebo-Controlled Trials and Spontaneous Reports Investigations:
Ved konstateret graviditet, bør behandling med AIIRA seponeres øjeblikkeligt, og hvis det skønnes hensigtsmæssigt, bør anden behandling iværksættes (se pkt.
When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Der kan forekomme hyperurikæmi, eller regulær urinsyregigt kan blive fremskyndet, hos visse patienter i thiazidbehandling.
Hyperuricaemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.
De bivirkninger, der er forbundet med hydrochlorthiazid, kan blive forstærket ved højere doser.
It is known that side effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.
Anafylaktisk reaktion/shock
Anaphylactic reaction including anaphylactic shock
Som det er tilfældet med ACE-hæmmere, kan samtidig anvendelse af angiotensin II-antagonister og NSAID medføre øget risiko for forværring af nyrefunktionen, herunder muligt akut nyresvigt samt øgning af serum-kalium.
As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Irbesartan/Hydrochlorthiazid Teva indeholder natrium
Irbesartan/Hydrochlorothiazide Teva contains sodium
Bivirkninger forbundet med hydrochlorthiazid alene
Side effects associated with hydrochlorothiazide alone are:
Svimmelhed, paræstesier, uklarhed, rastløshed
Vertigo, paraesthesia, lightheadedness, restlessness
Den ene side af tabletten er præget med tallet "93" og den anden side af tabletten er præget med tallet "7239".
One side of the tablet is debossed with the number “93” and the other side of the tablet is debossed with the number “7239”.
Ved ambulant blodtrykskontrol medførte kombinationen af 150 mg irbesartan og 12,5 mg hydrochlorthiazid, 1 gang dagligt, en vedvarende reduktion af blodtrykket over en 24 timers periode med en gennemsnitlig 24 timers placebo-korrigeret systolisk/diastolisk reduktion på 15,8/10,0 mm Hg.
When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebosubtracted systolic/diastolic reductions of 15.8/10.0 mmHg.
• i et 6 måneders toksicitetsstudie med irbesartan 90 mg/kg/dag, hydrochlorthiazid 90 mg/kg/dag,
6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day.
Risikominimerende foranstaltninger
Measures to mitigate the risk
Tag ikke medicin, der indeholder lithium, samtidig med at du tager Irbesartan/Hydrochlorthiazid Teva uden grundig vejledning fra lægen.
Preparations containing lithium should not be taken with Irbesartan/Hydrochlorothiaizde Teva without close supervision by your doctor.
Den ene side af tabletten er præget med tallet "93" og den anden side af tabletten er præget med tallet "7238".
One side of the tablet is debossed with the number “93" and the other side of the tablet is debossed with the number "7238".
Irbesartan omdannes i leveren ved konjugering som glucuronid og ved oxidation.
Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation.
Brug af Irbesartan/Hydrochlorthiazid Teva sammen med alkohol
Irbesartan/Hydrochlorothiazide Teva with alcohol
58 % af de inkluderede patienter var mænd.
The study recruited 58 % males.
Senest to år efter
Within 2 years after Commission Decision.
Irbesartan/Hydrochlorthiazid Teva må ikke anvendes til patienter med alvorlig nyrefunktionsnedsættelse (kreatininclearance < 30 ml/min) (se pkt.
Irbesartan/Hydrochlorothiazide Teva should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
4.4), hyperurikæmi, glukosuri, hyperglykæmi, stigning i kolesterol og triglycerider
Electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides
Der er ingen klinisk erfaring med Irbesartan/Hydrochlorthiazid Teva hos patienter med nedsat leverfunktion.
There is no clinical experience with Irbesartan/Hydrochlorothiazide Teva in patients with hepatic impairment.
Den anden side af tabletten er præget med tallet "7469".
The other side of the tablet debossed with the number "7469".
Ved hypotension lægges patienten i rygleje og salt- og væsketilskud administreres straks.
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
Din læge vil normalt anbefale, at du stopper med at tage Irbesartan/Hydrochlorthiazid Teva, inden du bliver gravid, eller så snart du ved, at du er gravid.
Your doctor will normally advise you to stop taking Irbesartan/Hydrochlorothiazide Teva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Irbesartan/Hydrochlorothiazide Teva.
Data fra kliniske studier har vist, at dobbelthæmning af renin-angiotensin-aldosteronsystemet (RAAS) gennem kombinationsbehandling med ACE-hæmmere, angiotensin II-receptorantagonister eller aliskiren er forbundet med en højere hyppighed af bivirkninger som hypotension, hyperkaliæmi og nedsat nyrefunktion (inklusive akut nyresvigt) sammenlignet med brug af et enkelt RAAS-virkende lægemiddel (se pkt.
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).
Irbesartan fjernes ikke ved hæmodialyse.
Irbesartan is not removed by haemodialysis.
Hvis du har glemt at tage Irbesartan/Hydrochlorthiazid Teva
If you forget to take Irbesartan/Hydrochlorothiazide Teva
Filmovertræk for styrken 300 mg/25 mg:
300 mg/25 mg strength:
Irbesartan/Hydrochlorthiazid Teva er ikke indiceret til patienter med svært nedsat leverfunktion.
Irbesartan/Hydrochlorothiazide Teva is not indicated in patients with severe hepatic impairment.
Virkningen af kombinationen af irbesartan/hydrochlorthiazid afhænger ikke af alder eller køn.
There is no difference in response to irbesartan/hydrochlorothiazide, regardless of age or gender.
For risikopatienter anbefales tilstrækkelig monitorering af serum-kalium (se pkt.
Adequate monitoring of serum potassium in patients at risk is recommended (see section
• Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg kan gives til patienter, hvis blodtryk ikke kan reguleres tilstrækkeligt med hydrochlorthiazid eller irbesartan 150 mg alene;
• Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Pakningsstørrelse a 28 filmovertrukne tabletter i enhedsdosisblistre.
Pack size of 28 film-coated tablets in non-perforated calendar blisters.
Filmovertræk for styrkerne 150 mg/12,5 mg og 300 mg/12,5 mg: Hypromellose
150 mg/12.5 mg and 300 mg/12.5 mg strengths: Hypromellose
Kontakt lægen, før du tager Irbesartan/Hydrochlorthiazid Teva, hvis du oplever følgende:
Talk to your doctor before taking Irbesartan/Hydrochlorothiazide Teva and if any of the following apply to you:
Brystsmerter
Cardiac arrhythmias
Kombinationen af en ACE-hæmmer og en angiotensin II-receptorantagonist er undersøgt i to store randomiserede, kontrollerede studier (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) og VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)).
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Ved meget høje doser (≥ 500 mg/kg/dag) inducerede irbesartan degenerative forandringer i nyrerne (fx interstitiel nefritis, tubulær udvidelse, basofile tubuli, øgede plasmakoncentrationer af carbamid og kreatinin) hos rotter og makakaber.
At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidneys (such as interstitial nephritis, tubular distention, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion.
Hvide, uigennemsigtige PVC-PVdC - aluminiumblistere: Må ikke opbevares ved temperaturer over 30 °C.
White opaque PVC-PVdC - Aluminium blisters: Do not store above 30°C.
Irbesartan/hydrochlorthiazid
Irbesartan/hydrochlorothiazide
For at minimere risikoen for hudkræft bør patienterne rådes til at træffe forebyggende foranstaltninger som f.eks. at begrænse eksponeringen for sollys og UV-stråler og, ved eksponering, at sørge for tilstrækkelig beskyttelse.
Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer.
Thiazidinduceret hypokaliæmi eller hypomagnesiæmi øger forekomsten af digitalisinducerede kardielle arytmier (se pkt.
Thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias (see section 4.4);
Bivirkninger, hvor hyppigheden ikke er kendt: hovedpine, ringen for ørerne, hoste, smagsforstyrrelser, forstoppelse, led- og muskelsmerter, leversygdom og nedsat nyrefunktion, øget mængde af kalium i blodet og allergiske reaktioner, såsom udslæt, nældefeber, opsvulmet ansigt, læber, mund, tunge og hals.
Undesirable effects where the frequency is not known are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat.
I to epidemiologiske studier baseret på det danske Cancerregister er der observeret øget risiko for nonmelanom hudkræft (basalcellekarcinom og pladecellekarcinom) ved en stigende kumulativ dosis af hydrochlorthiazid.
An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry.
Irbesartan/Hydrochlorthiazid Teva er tilgængelige i pakningsstørrelser med 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 og 100 filmovertrukne i ikke perforerede blisterpakninger; pakningsstørrelser med 50x1 filmovertrukken tablet i enhedsblisterpakninger og pakningsstørrelse med 28 filmovertrukne tabletter i ikke perforerede kalenderblisterpakninger.
Irbesartan/Hydrochlorothiazide Teva is available in pack sizes of 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters.
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter EU/1/09/583/049-072
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets EU/1/09/583/049-072
Indigotin (Indigocarmin) Sort jernoxid
Indigotine (Indigo carmine aluminium lake FD&C blue #2) Iron Oxide Black
Faldet i SeSBT/SeDBT ved 5 uger var henholdsvis 30,8/24,0 mm Hg og 21,1/19,3 mm Hg for irbesartan/hydrochlorthiazid og irbesartan (p < 0,0001).
The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p < 0.0001).
Dosering 1 gang dagligt med 150 mg irbesartan og 12,5 mg hydrochlorthiazid gav en systolisk/diastolisk gennemsnitlig placebojusteret blodtryksreduktion ved laveste måling (24 timer efter dosis) på 12,9/6,9 mm Hg hos patienter med let til moderat hypertension.
Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg in patients with mild-to-moderate hypertension.
Dog skal denne faste dosiskombination gives med forsigtighed til patienter med mild til moderat nedsat nyrefunktion (kreatininclearance ≥ 30 ml/min, men < 60 ml/min).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but < 60 ml/min) this fixed dose combination should be administered with caution.
Non-steroide antiinflammatoriske lægemidler Administration af et non-steroidt antiinflammatorisk lægemiddel kan reducere den diuretiske,
The administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg
Den anden side af tabletten er præget med tallet "7238".
The other side of the tablet debossed with the number "7238".
Stort forbrug af hydrochlorthiazid (≥ 50.000 mg kumulativt) var forbundet med en justeret OR-værdi på 1,29 (95 %KI: 1,23-1,35) for basalcellekarcinom og på 3,98 (95 %-KI: 3,68-4,31) for pladecellekarcinom.
(95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC.